Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

This is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel (TAK-700) plus prednisone compared with placebo plus prednisone in the treatment of men with progressive, chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC)

Study Overview

• Status: Completed
• Conditions: Prostate Cancer
• Intervention / Treatment: Drug: Orteronel; Drug: Prednisone; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 1560
• Phase: Phase 3

Contacts and Locations

Study Locations

• Australia
  • Garran, Australia
  • Hobart, Australia
  • Kurralta Park, Australia
  • Nedlands, Australia
  • Perth, Australia
  • Redcliffe, Australia
  • Wodonga, Australia
• Austria
  • Graz, Austria
  • Linz, Austria
  • Wien, Austria
• Belarus
  • Minsk, Belarus
• Belgium
  • Edegem, Belgium
  • Hasselt, Belgium
  • Kortrijk, Belgium
  • Leuven, Belgium
  • Namur, Belgium
• Brazil
  • Bairro Nazare - Salvador, Brazil
  • Barretos/sp, Brazil
  • Belo Horizonte, Brazil
  • Campinas, Brazil
  • Caxias Do Sul, Brazil
  • Curitiba, Brazil
  • Fortaleza/ce, Brazil
  • Ijui, Brazil
  • Joinville, Brazil
  • Lajeado - Rs, Brazil
  • Piracicaba - Sp, Brazil
  • Porto Alegre- Rs, Brazil
  • Porto Alegre/rs, Brazil
  • Ribeirao Preto - Sp, Brazil
  • Rio de Janeiro, Brazil
  • Rio de Janeiro Rj, Brazil
  • Santo Andre, Brazil
  • Sao Jose Do Rio Preto, Brazil
  • Sao Jose Dos Campos, Brazil
  • Sao Paulo, Brazil
  • Sorocaba - Sp, Brazil
• Bulgaria
  • Plovdiv, Bulgaria
  • Sofia, Bulgaria
  • Varna, Bulgaria
• Canada
  • British Columbia
    • Kelowna, British Columbia, Canada
  • Ontario
    • Burlington, Ontario, Canada
    • Hamilton, Ontario, Canada
    • London, Ontario, Canada
    • Owen Sound, Ontario, Canada
    • Toronto, Ontario, Canada
  • Quebec
    • Montreal, Quebec, Canada
    • Pointe Claire, Quebec, Canada
    • Quebec City, Quebec, Canada
    • Sherbrooke, Quebec, Canada
• Chile
  • Las Condes, Chile
  • Santiago, Chile
  • Temuco, Chile
  • Valparaiso, Chile
• Colombia
  • Cali, Colombia
• Czech Republic
  • Hradec Kralove, Czech Republic
  • Praha 4, Czech Republic
  • Praha 5, Czech Republic
• Finland
  • Joensuu, Finland
  • Oulu, Finland
  • Seinajoki, Finland
  • Tampere, Finland
• France
  • Angers, France
  • Bordeaux, France
  • Caen, France
  • Creteil, France
  • La Roche Sur Yon, France
  • Lyon, France
  • Marseille, France
  • Nancy, France
  • Nantes, France
  • Paris, France
  • Paris Cedex 13, France
  • Paris Cedex 14, France
  • Poitiers, France
  • Saint-etienne, France
  • Villejuif, France
• Germany
  • Braunschweig, Germany
  • Dresden, Germany
  • Hamburg, Germany
  • Hannover, Germany
  • Kassel, Germany
  • Kempen, Germany
  • Nurtingen, Germany
  • Tubingen, Germany
  • Wuppertal, Germany
• Greece
  • Athens, Greece
  • Heraklion Crete, Greece
  • Larissa, Greece
  • Patras, Greece
  • Thessaloniki, Greece
• Hong Kong
  • Kowloon, Hong Kong
  • Shatin, Hong Kong
• Ireland
  • Dublin, Ireland
  • Galway, Ireland
• Israel
  • Haifa, Israel
  • Holon, Israel
  • Jerusalem, Israel
  • Petach Tikva, Israel
  • Ramat-gan, Israel
  • Tel Aviv, Israel
  • Zerifin, Israel
• Italy
  • Aviano, Italy
  • Novara, Italy
  • Roma, Italy
  • Torino, Italy
• Japan
  • Chiba, Japan
  • Chiba-city, Japan
  • Fukuoka, Japan
  • Hamamatsu City, Japan
  • Hokkaido, Japan
  • Kanazawa, Japan
  • Kita-gun, Japan
  • Maebashi-city, Japan
  • Mito-city, Japan
  • Osaka, Japan
  • Osaka-city, Japan
  • Sakura City, Japan
  • Sayama, Japan
  • Sendai City, Japan
  • Shimizucho Sunto-gun, Japan
  • Suntou-gun, Japan
  • Tokyo, Japan
  • Yamagata City, Japan
  • Yokohama City, Japan
  • Yufu-city, Japan
• Latvia
  • Riga, Latvia
• Lithuania
  • Kaunas, Lithuania
  • Klaipeda, Lithuania
  • Vilnius, Lithuania
• Mexico
  • Durango Durango, Mexico
  • Mexico City Distrito Federal, Mexico
  • Zapopan Jalisco, Mexico
• Netherlands
  • Amsterdam, Netherlands
  • Arnhem, Netherlands
  • Breda, Netherlands
  • Eindhoven, Netherlands
  • Heerlen, Netherlands
  • Nieuwegein, Netherlands
  • Nijmegen, Netherlands
  • Rotterdam, Netherlands
• New Zealand
  • Auckland, New Zealand
  • Christchurch, New Zealand
  • Dunedin, New Zealand
  • Takapuna, New Zealand
  • Tauranga, New Zealand
• Peru
  • Lima, Peru
• Poland
  • Bielsko-biala, Poland
  • Wroclaw, Poland
• Portugal
  • Liepaja, Portugal
  • Lisboa, Portugal
  • Porto, Portugal
• Puerto Rico
  • San Juan, Puerto Rico
• Romania
  • Bucharest, Romania
  • Cluj-napoca, Romania
• Russian Federation
  • Moscow, Russian Federation
  • St Petersburg, Russian Federation
• Singapore
  • Singapore, Singapore
• Slovakia
  • Nitra, Slovakia
  • Presov, Slovakia
  • Trencin, Slovakia
  • Zilina, Slovakia
• South Africa
  • Cape Town, South Africa
  • Durban, South Africa
  • George, South Africa
  • Port Elizabeth, South Africa
• Spain
  • Barcelona, Spain
  • La Coruna, Spain
  • Madrid, Spain
  • Majadahonda, Spain
  • Pamplona, Spain
  • Sevilla, Spain
  • Valencia, Spain
• Sweden
  • Goteborg, Sweden
  • Stockholm, Sweden
  • Uppsala, Sweden
• Switzerland
  • Aarau, Switzerland
  • Lausanne, Switzerland
  • Winterthur, Switzerland
  • Zurich, Switzerland
• Taiwan
  • Taichung, Taiwan
  • Taipei, Taiwan
• Ukraine
  • Dnipropetrovsk, Ukraine
  • Donetsk, Ukraine
  • Kyiv, Ukraine
  • Zaporizhzhya, Ukraine
• United Kingdom
  • Aberdeen, United Kingdom
  • Belfast, United Kingdom
  • Bristol, United Kingdom
  • Cottingham, United Kingdom
  • Coventry, United Kingdom
  • Glasgow, United Kingdom
  • London, United Kingdom
  • Manchester, United Kingdom
  • Northwood, United Kingdom
  • Preston, United Kingdom
  • Southampton, United Kingdom
• United States
  • Alaska
    • Anchorage, Alaska, United States
  • Arizona
    • Tucson, Arizona, United States
  • California
    • Duarte, California, United States
    • Highland, California, United States
    • Orange, California, United States
    • Sacramento, California, United States
    • San Francisco, California, United States
  • Colorado
    • Aurora, Colorado, United States
    • Denver, Colorado, United States
  • Florida
    • Deerfield Beach, Florida, United States
    • Fort Myers, Florida, United States
    • Jacksonville, Florida, United States
    • Orlando, Florida, United States
    • Port St Lucie, Florida, United States
  • Indiana
    • Jeffersonville, Indiana, United States
  • Kansas
    • Kansas City, Kansas, United States
  • Louisiana
    • New Orleans, Louisiana, United States
  • Maryland
    • Baltimore, Maryland, United States
  • Massachusetts
    • Boston, Massachusetts, United States
  • Michigan
    • Lansing, Michigan, United States
  • Minnesota
    • Duluth, Minnesota, United States
  • Mississippi
    • Corinth, Mississippi, United States
  • Missouri
    • Columbia, Missouri, United States
    • Jefferson City, Missouri, United States
  • Nebraska
    • Omaha, Nebraska, United States
  • Nevada
    • Las Vegas, Nevada, United States
  • New Jersey
    • Hackensack, New Jersey, United States
  • New York
    • East Syracuse, New York, United States
    • New York, New York, United States
  • North Carolina
    • Durham, North Carolina, United States
    • Raleigh, North Carolina, United States
  • Ohio
    • Kettering, Ohio, United States
  • Oregon
    • Tualatin, Oregon, United States
  • Pennsylvania
    • Hershey, Pennsylvania, United States
    • Lancaster, Pennsylvania, United States
    • Philadelphia, Pennsylvania, United States
    • Piitsburgh, Pennsylvania, United States
  • South Carolina
    • Charleston, South Carolina, United States
    • Columbia, South Carolina, United States
  • Tennessee
    • Chattanooga, Tennessee, United States
    • Nashville, Tennessee, United States
  • Texas
    • Amarillo, Texas, United States
    • Bedford, Texas, United States
    • Dallas, Texas, United States
    • Denton, Texas, United States
    • Tyler, Texas, United States
  • Utah
    • Salt Lake City, Utah, United States
  • Virginia
    • Norfolk, Virginia, United States

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

Each patient must meet all of the following inclusion criteria:

• Voluntary written consent
• Male patients 18 years or older
• Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma
• Radiograph-documented metastatic disease
• Progressive disease
• Prior surgical castration or concurrent use of an agent for medical castration
• Either absence of pain or pain not requiring use of any opioid or narcotic analgesia in the 2 weeks prior to study entry
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• Even if surgically sterilized, patients must practice effective barrier contraception during the entire study treatment and for 4 months after the last dose of study drug, OR abstain from heterosexual intercourse
• Meet screening laboratory values as specified in protocol
• Stable medical condition

Exclusion Criteria:

Patients meeting any of the following exclusion criteria are not to be enrolled in the study:

• Known hypersensitivity to orteronel, prednisone or gonadotropin-releasing hormone (GnRH) analogue
• Received prior therapy with orteronel, aminoglutethimide, ketoconazole or abiraterone
• Received antiandrogen therapy within 6 weeks for bicalutamide and 4 weeks for all others prior to first dose of study drug
• Continuous daily use of oral prednisone or oral dexamethasone for more than 14 days within 3 months prior to study
• Received prior chemotherapy for prostate cancer with exception of neoadjuvant/adjuvant therapy as part of initial primary treatment for local disease that was completed 2 or more years prior to screening
• Exposure to radioisotope therapy within 4 weeks of receiving first dose of study drug; exposure to external beam radiation within 2 weeks of start of screening until receiving the first dose of study drug
• Documented central nervous system metastases
• Treatment with any investigational compound within 30 days prior to first dose of study drug
• Current spinal cord compression, bilateral hydronephrosis or current bladder neck outlet obstruction
• Diagnosis or treatment of another malignancy within 2 years preceding first dose of study drug except nonmelanoma skin cancer or in situ malignancy completely resected
• Uncontrolled cardiovascular condition as specified in study protocol
• Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
• Unwilling or unable to comply with protocol
• Uncontrolled nausea, vomiting or diarrhea
• Known gastrointestinal disease or procedure that could interfere with oral absorption or tolerance of orteronel

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: DOUBLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Orteronel + prednisone	Drug: Orteronel; Orteronel will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of <50 ng/dL.; Drug: Prednisone; Prednisone will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of <50 ng/dL.
PLACEBO_COMPARATOR: Placebo + prednisone	Drug: Prednisone; Prednisone will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of <50 ng/dL.; Drug: Placebo; Placebo will be administered orally twice a day continuously throughout the study. Additionally, all patients will receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and a testosterone concentration of <50 ng/dL.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Radiographic Progression-free Survival (rPFS)	rPFS was defined as the time from randomization to the first objective evidence of radiographic disease progression assessed by independent central radiology review or death due to any cause, whichever occurred first. Radiographic disease progression was evaluated by computerized tomography (CT) scan or magnetic resonance imaging (MRI) and radionuclide bone scans at regularly scheduled visits. Radiographic disease progression in bone required a confirmatory scan. Radiographic disease progression in soft tissue did not require a confirmatory scan for purposes of analysis. Radiographic disease progression was evaluated by independent central radiology review using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for soft tissue disease and Prostate Cancer Working Group (PCWG2) guidelines for bone disease. Participants who did not reach the endpoint were censored at their last assessment.	Baseline until radiographic disease progression or death, whichever occurred first (approximately up to 4.7 years)
Overall Survival	Overall survival was calculated from the date of participant randomization to the date of participant death due to any cause. Participants without documentation of death at time of the analysis were censored as of the date the participant was last known to be alive, or the data cutoff date, whichever was earlier.	Baseline until death (up to 4.7 years)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants Achieving 50 Percent Reduction From Baseline in Prostate Specific Antigen (PSA50) Response at Week 12	The PSA50 is defined as a decline of at least 50 percent (%) from baseline.	Week 12
Percentage of Participants With Favorable Circulating Tumor Cell Count (CTC) Levels at Week 12	A favorable CTC count was defined as less than <5 counts per 7.5 milliliter (mL) in whole blood. An unfavorable CTC count was defined as greater than or equal to (>=) 5 counts/7.5 mL in whole blood.	Week 12
Time to Pain Progression	Time to pain progression was defined as the time from participant randomization to the first assessment date of pain progression. Pain progression was defined as the occurrence of 1 of the following and confirmed by an additional assessment, at least 3 weeks but not more than 5 weeks later: The brief pain inventory-short form (BPI-SF) worst pain score was >=4 with a >=2 point increase over baseline in BPI-SF worst pain score with stable or increased analgesic use; The BPI-SF worst pain score was >=4 but not less than baseline with new or increased (relative to baseline) Step II or Step III analgesic use; The BPI-SF worst pain score was <=3 but not less than baseline with new or increased (relative to baseline) Step III analgesic use. BPI-SF was an 11-item questionnaire, designed to assess severity and impact of pain on daily functions. Total score ranged from 0 to 100 with lower scores being indicative of less pain or pain interference.	Baseline until End of treatment (EOT) (approximately up to 4.7 years)
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)		Baseline up to 30 days after last dose of study drug (Cycle 61 Day 58)
Number of Participants With Treatment-emergent Adverse Events Greater Than or Equal to (>=) Grade 3	Grade 3 (Severe) events=unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment. Grade 4 (Life-threatening) events caused participant to be in imminent danger of death. Grade 5 (Death) events=death related to an AE.	Baseline up to 30 days after last dose of study drug (Cycle 61 Day 58)
Number of Participants With TEAEs Related to Vital Signs		Baseline up to 30 days after last dose of study drug (Cycle 61 Day 58)
Number of Participants With TEAEs Related to Weight		Baseline up to 30 days after last dose of study drug (Cycle 61 Day 58)
Number of Participants With Worst Change From Baseline in Eastern Co-operative Oncology Group (ECOG) Performance Status	ECOG assessed participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (>50 percent of waking hours [hrs]), capable of all self care, unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair >50 percent of waking hrs; 4=completely disabled, cannot carry on any self care, totally confined to bed/chair; 5=dead. Worst change was defined as the worst overall change that occurred in ECOG status at any measured time point during the treatment period.	Baseline until EOT (approximately up to 4.7 years)
Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings		Baseline up to EOT (Cycle 61 Day 58)
Worst Change From Baseline Over Time in Cardiac Ejection Fraction	Worst change was defined as the worst overall change that occurred in cardiac ejection fraction at any measured time point.	Baseline up to 30 days or EOT whichever is later (approximately up to Cycle 61 Day 58)
Number of Participants With TEAEs Categorized Into Investigations Related to Chemistry, Hematology or Coagulation		Baseline up to 30 days or EOT whichever is later (approximately up to Cycle 61 Day 58)
Percentage of Participants With Skeletal Related Events (SRE)	Skeletal related (SRE) event is defined as a fracture or spinal cord compression or the need for radiation or surgery at the site of a prostate cancer metastatic lesion that is substantiated by radiographic or pathologic evidence.	Baseline up to EOT (approximately up to 4.7 years)
Time to SRE	Time to SRE is defined as the time from randomization to SRE, or death due to any cause, whichever comes first. SRE is defined as a fracture or spinal cord compression or the need for radiation or surgery at the site of a prostate cancer metastatic lesion that is substantiated by radiographic or pathologic evidence.	Baseline up to EOT (Cycle 61 Day 58)
Percentage of Participants Achieving PSA50 Response at Any Time During the Study	The PSA50 is defined as a decline of PSA by 50 percent from baseline.	Cycle: 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34 and 37
Percentage of Participants Achieving 90 Percent Reduction From Baseline in Prostate Specific Antigen (PSA90 Response) at Week 12	The PSA90 is defined as a decline of PSA by 90 percent from baseline.	Week 12
Percentage of Participants Achieving PSA90 Response at Any Time During the Study	The PSA90 is defined as a decline of PSA by 90 percent from baseline.	Cycle: 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34 and 37
Time to PSA Progression	Time to PSA progression was defined as time from randomization to a PSA increase of 25 percent and PSA rise of at least 2 nanogram per milliliter (ng/mL) above the lowest value observed post baseline or, if no PSA decline occurred post baseline, compared to baseline PSA.	Baseline until the final on treatment assessment or until end of short term follow-up following discontinuation of treatment, whichever occurred later (approximately up to 4.7 years)
Time to Docetaxel Chemotherapy	Time to docetaxel based chemotherapy is defined as the time from randomization to the start of docetaxel based chemotherapy for prostate cancer, regardless of whether the participant received concurrent orteronel or not. Deaths due to disease progression prior to Docetaxel based chemotherapy were considered as events.	Baseline until start of docetaxel chemotherapy (up to 4.7 years)
Time to Subsequent Antineoplastic Therapy	Time to subsequent antineoplastic therapy is defined as the time from randomization to the start of any alternate antineoplastic therapy for prostate cancer. Deaths due to disease progression prior to antineoplastic therapy for prostate cancer are considered as events. Otherwise, time to next therapy is censored at the date of death or the last date the participant was known to be alive or the data cutoff date, whichever is earlier.	Baseline until start of subsequent antineoplastic therapy (up to 4.7 years)
Percentage of Participants With Objective Response	Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1. A CR was defined as the disappearance of all target lesions determined by computerized tomography (CT) or MRI. Any pathological lymph nodes (whether target or non-target) must have had reduction in short axis to <10 millimetre (mm). A PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of longest diameters of non-lymph node lesions and of the short diameter or short axis of lymph nodes.	Baseline until disease progression or death, whichever occurred first (approximately up to 4.7 years)
Time to Deterioration in Global Health Status	Global health status deterioration is defined as a drop greater than 16 points from the baseline assessment, confirmed at least 3 weeks later, on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core Module 30 (EORTC QLQ-C30) index after the score has been linearly transformed to a 0 to 100 scale. EORTC QLQ-C30 consists of 30 questions, where question 1 to 28 can be answered with 1: Not at all, 2: A little, 3: Quite a bit, 4: Very much and question 29 to 30 with 1: Very poor to 7: Excellent. For subscales a high score from 0-100 indicates: high global quality of life, high level of functioning (physical, role, emotional, cognitive, social) or a high level of symptoms (fatigue, nausea, pain, dyspnea, insomnia, appetite loss, constipation, diarrhoea, financial difficulties).	Baseline until EOT (approximately up to 4.7 years)

Collaborators and Investigators

• Sponsor: Millennium Pharmaceuticals, Inc.

Publications and helpful links

General Publications

• Heller G, McCormack R, Kheoh T, Molina A, Smith MR, Dreicer R, Saad F, de Wit R, Aftab DT, Hirmand M, Limon A, Fizazi K, Fleisher M, de Bono JS, Scher HI. Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. J Clin Oncol. 2018 Feb 20;36(6):572-580. doi: 10.1200/JCO.2017.75.2998. Epub 2017 Dec 22.
• Suri A, Chapel S, Lu C, Venkatakrishnan K. Physiologically based and population PK modeling in optimizing drug development: A predict-learn-confirm analysis. Clin Pharmacol Ther. 2015 Sep;98(3):336-44. doi: 10.1002/cpt.155. Epub 2015 Jul 14.
• Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, MacLean DB, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Webb IJ, de Wit R; ELM-PC 4 investigators. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol. 2015 Mar;16(3):338-48. doi: 10.1016/S1470-2045(15)70027-6. Epub 2015 Feb 18.

Study record dates

Study Major Dates

• Study Start (ACTUAL): October 1, 2010
• Primary Completion (ACTUAL): January 1, 2014
• Study Completion (ACTUAL): April 7, 2016

Study Registration Dates

• First Submitted: August 31, 2010
• First Submitted That Met QC Criteria: August 31, 2010
• First Posted (ESTIMATE): September 1, 2010

Study Record Updates

• Last Update Posted (ACTUAL): May 17, 2017
• Last Update Submitted That Met QC Criteria: April 7, 2017
• Last Verified: April 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Genital Neoplasms, Male; Prostatic Diseases; Prostatic Neoplasms; Physiological Effects of Drugs; Anti-Inflammatory Agents; Antineoplastic Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Prednisone
• Other Study ID Numbers: C21004; 2010-018661-35 (EUDRACT_NUMBER); 0991413276 (OTHER: TCTIP); 10/H0406/75 (REGISTRY: NRES); U1111-1181-0387 (REGISTRY: WHO)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes